Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Wednesday<br />
March 6 Oral Sessions<br />
Session 45 CROI <strong>2013</strong><br />
248 Phenotypic Differences Between Transmitted/Founder<br />
and Chronic Env Proteins Revealed by Quantitative,<br />
High-Throughput Receptor Affinity Profiling<br />
Kelechi Chikere* 1 , N Webb 1 , T Chou 1 , P Gorry 2 , and B Lee 1<br />
1 Univ of California, Los Angeles, US and 2 Burnet Inst, Melbourne, Australia<br />
249 Transmitted/Founder Infectious Molecular Clones<br />
of Divergent SIV smm Strains Are Infectious and<br />
Replication Competent in vivo<br />
D Ma 1 , H Li 2 , C Xu 1 , B Keele 3 , J Estes 3 , J Lifson 3 , I Pandrea 1 , G Shaw 2 ,<br />
B Hahn 2 , and Cristian Apetrei* 1<br />
1 Ctr for Vaccine Res, Univ of Pittsburgh, PA, US;; 2 Univ of Pennsylvania<br />
Perelman Sch of Med, Philadelphia, US;; and 3 Frederick Natl Lab, MD, US<br />
250 The Number and Genetic Relatedness of<br />
Transmitted/Founder Virus Impact Clinical<br />
Outcome in Vaginal R5 SHIV SF162P3N Transmission<br />
Lily Tsai* 1 , I Tasovski 2 , AR Leda 1 , M Chin 2 , and C Cheng-Mayer 1<br />
1 Aaron Diamond AIDS Res Ctr, New York, NY, US and 2 Temple Univ Sch of<br />
Med, Philadelphia, PA, US<br />
b Wednesday, 1:30-2:30 pm; B308<br />
Session 46–Themed Discussion<br />
(see Session 127 on Tuesday for corresponding Poster Abstracts)<br />
Emergence and Persistence of HPV-associated<br />
Malignancies in the ART Era<br />
Discussants:<br />
Elizabeth Chiao , Baylor Coll of Med, Houston, TX, US<br />
Cynthia Firnhaber, Univ of the Witwatersrand, Johannesburg, South Africa<br />
730 AIDS-defining Cancers in Switzerland 1985-2011:<br />
Separating the Effects of Age and Period<br />
F Schoni-Affolter1 , L Elzi2 , R Weber3 , A Calmy4 , A Bregenzer5 ,<br />
M Cavassini6 , H Furrer7 , G Clifford8 , M Egger1 , Olivia Keiser* 1 ,<br />
and Swiss HIV Cohort Study<br />
1 2 3 Univ of Bern, Switzerland;; Univ Hosp Basel, Switzerland;; Univ Hosp<br />
Zurich, Switzerland;; 4Geneva Univ Hosp, Switzerland;; 5Cantonal Hosp St<br />
Gallen, Switzerland;; 6Univ Hosp Lausanne, Switzerland;; 7Univ Hosp Bern,<br />
Switzerland;; and 8Intl Agency for Res on Cancer<br />
731 Incidence of AIDS-defining and Non-AIDS-defining<br />
Cancers following Expansion of ART: Botswana<br />
2003-2008<br />
Scott Dryden-Peterson* 1,2,3 , H Medhin4 , G Seage2 , M Pusoentsi4 , S El-Halabi4 ,<br />
T Rebbeck5 , G Suneja5 , M Mmalane3 , M Essex2,3 , and S Lockman1,2,3 1 2 Brigham and Women�s Hosp, Boston, MA, US;; Harvard Sch of Publ Hlth,<br />
Boston, MA, US;; 3Botswana Harvard AIDS Inst Partnership, Gaborone;;<br />
4 5 Botswana Ministry of Hlth, Gaborone;; and Univ of Pennsylvania,<br />
Philadelphia, US<br />
732 Frequent Detection of Human Papillomavirus before<br />
and after Initiation of ART among HIV + Women:<br />
Uganda<br />
Anne Rositch* 1 , P Gravitt1,2 , A Tobian1,3 , K Newell4 , T Quinn3,5 ,<br />
D Serwadda6 , P Ssebbowa6 , V Kiggundu6 , R Gray1,6 , and S Reynolds3,5 1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;;<br />
2 3 Perdana Univ Grad Sch of Med, Serdang, Malaysia;; Johns Hopkins Univ<br />
Sch of Med, Baltimore, MD, US;; 4Frederick Natl Lab for Cancer Res, MD, US;;<br />
5 6 NIAID, NIH, Bethesda, MD, US;; and Rakai Hlth Sci Prgm, Entebbe, Uganda<br />
733 HPV Genotype Impacts T Cell Activation and<br />
Cervical Cellular Infiltrates Irrespective of Lesion<br />
Grade in ART-suppressed Human Papillomavirus/<br />
HIV-1 Co-infected Women<br />
Emmanouil Papasavvas* 1 , D Glencross2,3 , N Mayisela4 , T Omar2 ,<br />
A-L Williamson5,6 , M Siminya4 , X Yin1 , Q Liu1 , C Firnhaber2,4 ,<br />
and L Montaner1 1 2 The Wistar Inst, Philadelphia, PA, US;; Univ of the Witwatersrand,<br />
Johannesburg, South Africa;; 3Natl Hlth Lab Svc, Johannesburg, South<br />
Africa;; 4Right to Care, Johannesburg, South Africa;; 5Univ of Cape Town,<br />
South Africa;; and 6Natl Hlth Lab Svc, Cape Town, South Africa<br />
734 Human Papillomavirus, Cervical Neoplasia, and<br />
Invasive Cancer in Women with HIV-2 Infection in<br />
the ART Era: Senegal, West Africa<br />
S Hawes1 , Q Feng1 , S Ba2 , M Toure1,2 , M-P Sy2 , F Traore2 , R Smith1 , N Kiviat1 ,<br />
PS Sow1,2 , Geoffrey Gottlieb* 1 , and UW-Dakar HIV-2 Study Group<br />
1 2 Univ of Washington, Seattle, US and Ctr Hosp Univ de Fann, Univ Cheikh<br />
Anta Diop de Dakar, Senegal<br />
735 Anal Human Papillomavirus Infection in HIV +<br />
Patients: Prevalence, Incidence, and Predictors<br />
of High-risk Human Papillomavirus Infection<br />
Alberto Borghetti* 1 , P Cattani2 , G Maria3 , M Sanguinetti2 ,<br />
S D’Onghia2 , R Santangelo2 , S Marchetti2 , R Cauda1 , A De Luca1,4 ,<br />
and S Di Giambenedetto1 1Inst of Clin Infectious Diseases, Catholic Univ of Sacred Heart, Rome,<br />
Italy;; 2Inst of Microbiology, Catholic Univ of Sacred Heart, Rome, Italy;;<br />
3Inst of Clin and Surgical Therapy, Catholic Univ of Sacred Heart, Rome,<br />
Italy;; and 4Siena Univ Hosp, Italy<br />
20 � 20th Conference on Retroviruses and Opportunistic Infections<br />
736 The Effect of Protease Inhibitors on the Incidence of<br />
HIV-associated Squamous Cell Carcinoma of the Anus<br />
Pamela Mbang* 1 , M Kowalkowski 2 , and E Chiao 1,2<br />
1 Baylor Coll of Med, Houston, TX, US and 2 Houston Hlth Svcs Res and Devt<br />
Ctr of Excellence, Michael E DeBakey VAMC, TX, US<br />
737 Prevalence and Genotypes of Human Papillomavirus at<br />
Penile and Perianal Sites among HIV + and HIV – MSM<br />
Han-Zhu Qian* 1 , Y Hu 2 , L Yin 1 , Y Ruan 2 , Y Shao 2 , and S Vermund 1<br />
1 Vanderbilt Univ, Nashville, TN, US and 2 Natl Ctr for STD/AIDS Control<br />
and Prevention of China CDC, Beijing<br />
b Wednesday, 1:30-2:30 pm; B313<br />
Session 47–Themed Discussion<br />
(see Session 149 on Tuesday for corresponding Poster Abstracts)<br />
Mechanisms of Immune Reconstitution<br />
Discussants:<br />
Brigitte Autran, Univ Pierre and Marie Curie, Pitie-Salpetriere Hosp,<br />
Paris, France (invited)<br />
Robert Colebunders, Inst of Tropical Med Antwerp, Belgium<br />
859 Early ART after Cryptococcal Meningitis Increases<br />
Cerebrospinal Fluid Macrophage Activation and<br />
Aberrant Th2 Responses in a Multisite Randomized Trial<br />
James Scriven* 1,2 , J Rhein 3,4 , K Huppler Hullsiek 4 , M von Hohenberg 4 ,<br />
G Linder 4 , M Rolfes 4 , D Williams 3,4 , D Meya 3,4,5 , G Meintjes 2 , D Boulware 4 ,<br />
and Cryptococcal Optimal ART Timing Trial<br />
1 Liverpool Sch of Tropical Med, UK;; 2 Univ of Cape Town, South<br />
Africa;; 3 Infectious Disease Inst, Kampala, Uganda;; 4 Univ of Minnesota,<br />
Minneapolis, US;; and 5 Makerere Univ, Kampala, Uganda<br />
860 Impact of TB-associated Immune Reconstitution<br />
Inflammatory Syndrome on T Cell Activation and<br />
Reconstitution in Highly Immunosuppressed HIV/TB<br />
Co-infected Patients Starting ART<br />
V Haridas 1 , P Pean 2 , L Jasenosky 1 , Y Madec 3 , D Laureillard 4 , L Borand 2 ,<br />
O Marcy 5 , T Sok 5 , X Blanc 6 , and Anne Goldfeld* 1,5<br />
1 Prgm in Cellular and Molecular Med, Children�s Hosp, Boston, MA, US;;<br />
2 Inst Pasteur du Cambodge, Phnom Penh, Cambodia;; 3 Inst Pasteur, Paris,<br />
France;; 4 ANRS, Ho Chi Minh City, Vietnam;; 5 Cambodian Hlth Committee,<br />
Phnom Penh;; and 6 Bicetre Hosp Assistance Publ-Hosp de Paris, France<br />
861 Ex vivo Interferon Gamma Release Assay Responses<br />
to Cryptococcal Capsule Antigen Predict Outcomes<br />
of Death or Immune Reconstitution Inflammatory<br />
Syndrome after Cryptococcal Meningitis<br />
Darin Wiesner* 1 , A Akamps 2 , J Rhein 1,3 , D Williams 1,3 , D Meya 1,2,3 ,<br />
P Bohjanen 1 , K Nielsen 1 , D Boulware 1 , and Cryptococcal Optimal ART<br />
Timing Trial<br />
1 Univ of Minnesota, Minneapolis, US;; 2 Makerere Univ, Kampala, Uganda;;<br />
and 3 Infectious Disease Inst, Kampala, Uganda<br />
862 Biomarkers of CD4 + T Cell Activation in HIV +<br />
Patients Developing Mycobacterium tuberculosisassociated<br />
Immune Reconstitution Inflammatory<br />
Syndrome<br />
Lisa Chakrabarti* 1 , C Boucherie 2 , F Bugault 1 , M-C Cumont 1 ,<br />
C Roussillon 2 , G Breton 3 , O Patey 4 , L Richert 2 , G Chene 2,5 , O Lortholary 6 ,<br />
and ANRS 129 BKVIR-CYTOK Substudy Group<br />
1 Inst Pasteur, Paris, France;; 2 INSERM U897, Univ Bordeaux, France;;<br />
3 Hosp de La Pitie-Salpetriere, Paris, France;; 4 Hosp Villeneuve St-Georges,<br />
France;; 5 CHU de Bordeaux, France;; and 6 Univ Paris Descartes, Hosp<br />
Necker Enfants Malades, APHP, Paris, France<br />
b Wednesday, 1:30-2:30 pm; Ballroom 3-4<br />
Session 48–Themed Discussion<br />
(see Session 198 on Tuesday for corresponding Poster Abstracts)<br />
Adherence and Retention in RLS<br />
Discussants:<br />
David Bangsberg, Massachusetts Gen Ctr for Global Hlth, Boston, US<br />
Wafaa El-Sadr, Columbia Univ, Harlem Hosp Ctr, New York, NY, US<br />
1101 Validating Measures of Distance to HIV Clinic in<br />
Rural Uganda and Its Impact on Clinic Attendance<br />
Mark Siedner* 1 , A Lankowski 1 , A Tsai 1,2 , C Muzoora 3 , P Hunt 4 ,<br />
J Martin 4 , J Haberer 1 , and D Bangsberg 1,5<br />
1 Massachusetts Gen Hosp Ctr for Global Hlth, Boston, US;; 2 Massachusetts<br />
Gen Hosp, Boston, US;; 3 Mbarara Univ of Sci and Tech, Uganda;; 4 Univ<br />
of California, San Francisco, US;; and 5 Ragon Inst of MGH, MIT, and<br />
Harvard Med Sch, Boston, US<br />
1102 Site and Program Determinants of Patient Retention<br />
in HIV Care: Nigeria<br />
Chinenye Ugoji* 1 , R Ake-Uzoigwe 1 , MY Ladele 1 , C Akolo 1 , G Mendy 1 ,<br />
P Dakum 1 , M Charurat 2 , D Onotu 3 , O Nwanyanwu 3 , and W Blattner 2<br />
1 Inst of Human Virology Nigeria, Abuja;; 2 Inst of Human Virology, Univ of<br />
Maryland, Baltimore, US;; and 3 Ctr for Disease Control, Nigeria
Change language